In the treatment of relapsed and refractory multiple myeloma, the anti-CD38 monoclonal antibody SAR650984 effectively killed resistant multiple myeloma cells by increasing CTSB throughout the cytoplasm 153. Here, CTSB is linked to plasma cell myeloma.